

Table 1: the relationship between expression levels of CHIP or CAD and clinicopathological features in glioma patients

Variables	CAD			CHIP		
	n=667cases			n=667cases		
	Low (%)	High (%)	<i>P value</i>	Low (%)	High (%)	<i>P value</i>
All patients	573	94		67	600	
Gender			0.814			0.352
Males	306	49		34	321	
Females	217	37		31	223	
Age (years)			0.8668			0.85
>65	71	12		8	75	
≤ 65	452	74		57	469	
Histology			0.226			0.031
GBM	125	27		17	135	
Astro	167	27		27	167	
Oliga	118	12		13	117	
Oligd	163	28		10	181	
Grade			<0.001			0.002
II	210	16		12	214	
III	199	45		36	208	
IV	122	27		17	132	
Status*			0.001			0.002
0	382	46		31	397	
1	191	48		36	203	
1P/19q codeletion			0.250			<0.001
Codel	150	19		2	167	
Non-codel	417	75		63	429	
MGMT promoter status			0.689			0.001
Methylated	414	63		38	439	

Unmethylated	136	23	28	131
IDH Status			0.0265	<0.001
mutant	377	51	29	399
WT	189	43	38	194

- 3 GBM, Glioblastoma. Astro, Oligoastrocytoma. Oligd, Oligodendroglioma. Oliga,
- 4 Oligoastrocytoma. WT, Wild Type. Status*-0, aLive. Status*-1, death. Codel,
- 5 Codeletion. Non-codel, non-codeletion.